Exacerbation of COPD after a COVID 19-Booster Vaccine

A 75-year-old African American woman presented to the Emergency Department (ED) complaining of shortness of breath, cough and a drop in her oxygen saturation (SpO2) from her baseline of 95%–88%. 

She received a Pfizer COVID 19 booster vaccine one day before her symptoms began. The patient had received the Johnson & Johnson COVID-19 vaccine 11 months prior without a notable reaction.  She had a history of chronic obstructive pulmonary disease (COPD) but was not on any home oxygen. 

Upon admission the patient had an SpO2 of 82% and a heart rate of 101 beats per minute. Notably, she was afebrile, with a temperature of 36.6 °C. On physical exam the patient was noted to be wheezing and breathing with difficulty. She tested negative for a variety of respiratory viruses including COVID-19. A chest radiograph (x-ray) demonstrated subtle patchy opacifications consistent with a COPD exacerbation, and no consolidations or pleural effusions. A normal cardiac silhouette was also observed.

After treatment, she was slowly weaned off supplemental oxygen over the course of her 5-day hospitalization and sent home.

A 76-year-old male with past medical history significant for lung adenocarcinoma stage IIB on chemotherapy, severe COPD, chronic hypoxic respiratory failure, low grade non-Hodgkin's lymphoma in remission, hypertension, gout, hear failure, that presents with fever 102F, and shortness of breath experienced life-threatening shortness of breath 24 hours after his 2nd dose of mRNA-1273 (Moderna COVID-19 vaccine). Fever and shortness of breath improved with systemic steroids. Patient remained stable on his home dose of oxygen supplementation while inpatient and was successfully discharged to home with prednisone taper. 


Several cases of COPD patients who died shortly after vaccine administration have been also reported. Postvaccination acute hypoxemic respiratory failure (46.3%), septic shock (24.4%), and cardiogenic shock (12.2%) were the most common causes of death.


REFERENCES

Gatenby W, Dominah G, Paudel A, Saleh N. A Chronic Obstructive Pulmonary Disease Exacerbation Following the Administration of a COVID 19-Booster Vaccine: A Case Report. Journal of Community Hospital Internal Medicine Perspectives. 2022;12(5):110-3.

Durdevic M, Arora A, Durdevic D, Stan AC, Naaraayan A. Acute COPD Exacerbation After The Second Dose of COVID-19 Vaccine. Chest. 2021 Oct 1;160(4):A1760.

Kewan T, Flores M, Mushtaq K, Alwakeel M, Burton R, Campbell J, Perry H, Al‐Jaghbeer M, Abi Fadel F. Characteristics and outcomes of adverse events after COVID‐19 vaccination. Journal of the American College of Emergency Physicians Open. 2021 Oct;2(5):e12565.

Comments

Post a Comment

Popular posts from this blog

A New Onset of Ulcerative Colitis post-2nd-breakthrough-COVID-19

Image
A 21-year-old non-smoking Caucasian male with a history of acute pancreatitis but no other medical issues or family history had two doses of the BNT162b2 mRNA COVID-19 vaccine.  Four months after the second dose he had his first episode of COVID-19. Although not hypoxic, he felt pretty unwell for a week, with a severe cough, fever, generalized body ache, headache, and loss of taste. He received the third dose of the vaccine two months after recovering from COVID. Nine months after the third dose, he had the second episode of COVID-19, during which he was mildly unwell for three days, recovered, and did not require any anti-viral medication or antibiotics. One week post the second episode of COVID-19, he developed diarrhea and abdominal pain. It then progressed to bloody diarrhea. Ulcerative colitis was diagnosed based on his clinical symptoms, biopsy changes, and the exclusion of other causes.  There are ten published case reports about the newly diagnosed ulcerative colitis associate
Read more

COVID in May

Image
Concerns about a potential resurgence of COVID-19 are mounting as summer 2024 approaches.  This is driven by several indicators, including social media posts, healthcare data, and wastewater surveillance across different regions. Our study findings corroborate this trend.  While many forecasters anticipate a surge, others expect a gradual increase through the end of May, and then a decline again around early June. Reports from social media suggest emerging clusters of COVID-19 in Texas, several Canadian provinces, the UK, and on cruises in northern regions such as a Norwegian cruise to Alaska.  Data from Alberta's Respiratory virus dashboard   (total weekly laboratory-confirmed COVID-19 cases) and wastewater surveillance in Calgary indicate an uptick in COVID-19 cases starting April 2024. The most recent statistics from Alberta Health reveal a significant increase in hospitalizations due to COVID-19, with 114 individuals currently hospitalized—an increase of more than 20% over two
Read more

Chronic SARS-CoV-2 Shedding

Image
Chronic viral shedding, a condition where the virus continues to be released from an individual's body long after the initial infection, has been observed in many infectious diseases, including COVID-19.  In such cases, individuals may remain asymptomatic or experience only mild symptoms while the virus persists. It remains detectable in repeated tests over an extended period and can still infect others even in nasal swab is negative (which happens quite often ). This was evident in our study.    Recent research by Conway et al. (2024) highlights the possibility of chronic SARS-CoV-2 infection, extending over several months and potentially years. Other studies have documented prolonged asymptomatic infections and extended viral shedding in moderate to severe beyond hospital discharge. Analysis of sequencing data on UK samples taken between 2 November 2020 and 15 August 2022 lead to estimates that 0.1–0.5% of infections may become persistent with typically rebounding high viral load
Read more